Pfizer aims to submit trial data for children aged five to 11 ‘this month’ | The Business Standard
Skip to main content
  • Latest
  • Epaper
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Thursday
June 19, 2025

Sign In
Subscribe
  • Latest
  • Epaper
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
THURSDAY, JUNE 19, 2025
Pfizer aims to submit trial data for children aged five to 11 ‘this month’

Coronavirus chronicle

TBS Report
08 September, 2021, 06:05 pm
Last modified: 08 September, 2021, 08:51 pm

Related News

  • Three children drown in ponds within an hour in Kutubdia
  • 10 more Covid-19 cases reported in country
  • Stillbirths in Bangladesh: A preventable public health emergency
  • Adolescence: A series parents must see
  • Dengue in children: Doctor shares warning signs for parents to watch out

Pfizer aims to submit trial data for children aged five to 11 ‘this month’

The pharmaceutical giant announced in March that it had launched a series of clinical trials to test two doses of its vaccine, developed with the German firm BioNTech, in children as young as six months old

TBS Report
08 September, 2021, 06:05 pm
Last modified: 08 September, 2021, 08:51 pm
Syringe and vial are seen in front of displayed new Pfizer logo in this illustration taken, June 24, 2021. REUTERS/Dado Ruvic/Illustration
Syringe and vial are seen in front of displayed new Pfizer logo in this illustration taken, June 24, 2021. REUTERS/Dado Ruvic/Illustration

The Pfizer coronavirus vaccine could soon be given to children as young as 5 years old, with the company is set to submit its trial data to the regulators this month. 

The pharmaceutical giant announced in March that it had launched a series of clinical trials to test two doses of its vaccine, developed with the German firm BioNTech, in children as young as six months old, reports the Telegraph.

According to Pfizer's chief executive, Dr Albert Bourla, results from the older cohort of participants – aged between five and 11 – are set to be submitted to regulators before the end of September. 

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

"We know that the vaccine works very well in young kids," he told journalists on Tuesday. "We are working also to submit data from five to 11 [year olds] this month."

Reports from the New York Times suggest results for children aged between two and five are expected shortly afterward, while data on infants aged between six months and two years could be submitted in October or November. 

It is likely that, in line with Pfizer's approach to approval for the booster shots, the data on five to 11-year-olds will first be submitted to the US Food and Drug Administration, reports the Telegraph.

The trial is testing a two-shot regimen 21 days apart, but with a slightly smaller dosage – 10 micrograms, rather than the 30 micrograms used in children and adults over 12. 

Dr Bourla's comments come amid increasingly fraught discussions around whether to vaccinate children in the UK. 

While more than 10 million children over 12 have been given Covid jabs in the United States, the UK's Joint Committee on Vaccinations and Immunisations (JCVI) has taken a more cautious approach, advising that only "high risk" children with certain underlying conditions receive a vaccine. 

For healthy children, the committee argued, the benefits of a jab only "marginally" outweigh the risks, and the longer-term impacts remain hazy. Much of the concern focuses around reports of myocarditis, a very rare but potentially fatal swelling of the heart muscle linked to the mRNA vaccines. 

But during Tuesday's briefing, hosted by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), Dr Bourla said the science supports vaccinating children, reports the Telegraph. 

"It is not my role to say who should be receiving doses," he said. "But what I can say, clearly, is that younger ages are getting sick... the percentage of people that will get severe [Covid] in older ages is higher than in younger, but this [risk] is not zero. 

"The other thing that we need to understand is that kids attend school. And because of that, the kids have a much higher probability [of getting] infected, as they socialise in high proximity with other kids.

"We know that the vaccines work very well in young kids," Dr Bourla said, adding that the Pfizer shot has already been approved in children over 12 in much of the world. 

In the UK, the increasingly fractious debate about whether or not to vaccinate children is expected to reach a conclusion this week.

The UK's chief medical officers are set to make a final decision on whether to follow the JCVI's advice or overrule it following a broader analysis of the societal impacts of vaccinations, reports the Telegraph.

Top News

Pfizer COVID vaccine / Coronavirus / children

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Illustration: TBS
    Bribery rampant in public services: BRTA tops list, law enforcement close behind, finds BBS survey
  • Prof Ali Riaz speaks at a press briefing at the LD Hall of the Jatiya Sangsad Complex in Dhaka. File photo: TBS
    Most parties agreed upon amending Constitution clause on presidential election process, says Ali Riaz
  • A drone photo shows the damage over residential homes at the impact site following missile attack from Iran on Israel, in Tel Aviv, Israel June 16, 2025. Photo: REUTERS/Moshe Mizrahi/File Photo
    Israel threatens to 'eliminate' Iran supreme leader Khamenei after Iranian missile strike

MOST VIEWED

  • Logo of Beximco Group. Photo: Collected
    Beximco defaults on €33m in Germany, Deshbandhu owes Czech bank €4m
  • The India-Bangladesh integrated checkpost in Fulbari. Photo: Passang Yolmo via Telegraph India
    Import of boulders from Bhutan to Bangladesh stopped by Indian transporters in Fulbari
  • Infograph: TBS
    End of a loophole: Defaulters on foreign loans barred from local bank borrowing
  • Smoke rises following an Israeli attack on the IRIB building, the country's state broadcaster, in Tehran, Iran, June 16, 2025. Majid Asgaripour/WANA (West Asia News Agency) via REUTERS
    Israel-Iran War: Russia says Israel's attacks illegal, UAE warns of 'uncalculated, reckless steps'
  • An anti-missile system operates as missiles are launched from Iran, as seen from Tel Aviv, Israel, 18 June 2025. Photo: Reuters
    Khamenei rejects Trump's demand for surrender, Trump says 'good luck'
  • Soldiers salute Arakan Army chief Major General Twan Mrat Naing during a parade in Myanmar, 6 April 2018. File Photo: Arakan Army deputy chief Brig Gen Nyo Twan Awng/Twitter
    Rohingya militant groups recruit from camps to fight Arakan Army, warns Crisis Group

Related News

  • Three children drown in ponds within an hour in Kutubdia
  • 10 more Covid-19 cases reported in country
  • Stillbirths in Bangladesh: A preventable public health emergency
  • Adolescence: A series parents must see
  • Dengue in children: Doctor shares warning signs for parents to watch out

Features

Evacuation of Bangladeshis: Where do they go next from conflict-ridden Iran?

Evacuation of Bangladeshis: Where do they go next from conflict-ridden Iran?

21h | Panorama
The Kallyanpur Canal is burdened with more than 600,000 kilograms of waste every month. Photo: Courtesy

Kallyanpur canal project shows how to combat plastic pollution in Dhaka

1d | Panorama
The GLS600 overall has a curvaceous nature, with seamless blends across every panel. PHOTO: Arfin Kazi

Mercedes Maybach GLS600: Definitive Luxury

3d | Wheels
Renowned authors Imdadul Haque Milon, Mohit Kamal, and poet–children’s writer Rashed Rouf seen at Current Book Centre, alongside the store's proprietor, Shahin. Photo: Collected

From ‘Screen and Culture’ to ‘Current Book House’: Chattogram’s oldest surviving bookstore

4d | Panorama

More Videos from TBS

What does Jamaat say about the power of the President and elections?

What does Jamaat say about the power of the President and elections?

6m | TBS Today
What is the government saying about the 'July Uprising Day' and the 'July Declaration'?

What is the government saying about the 'July Uprising Day' and the 'July Declaration'?

21m | TBS Today
Army says will carry out election-related duties in line with govt directive

Army says will carry out election-related duties in line with govt directive

1h | TBS Today
Americans oppose U.S. intervention in Iran

Americans oppose U.S. intervention in Iran

2h | TBS World
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net